Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5% – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) traded down 5.5% during mid-day trading on Monday . The stock traded as low as $12.13 and last traded at $12.13. 287,447 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 757,702 shares. The stock had previously closed at $12.83.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings initiated coverage on shares of Kailera Therapeutics in a research note on Friday, August 14th. They issued a “sell (d)” rating for the company. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Price Performance

The stock has a 50 day moving average of $16.74. The stock has a market cap of $1.66 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, research analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State Street Corp purchased a new stake in Kailera Therapeutics in the second quarter valued at approximately $19,126,000. Tidal Investments LLC purchased a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at $309,000. Squarepoint Ops LLC bought a new stake in shares of Kailera Therapeutics during the 2nd quarter worth $993,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics in the second quarter worth $24,233,000. Finally, Atlas Venture Life Science Advisors LLC bought a new position in Kailera Therapeutics in the second quarter valued at $113,923,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.